We are pleased to report a successful 2022, as we were able to manage our business to deliver 17% revenue growth and continued positive cash flow from operations.  

Despite ongoing external challenges, we made significant progress toward our mission of providing quality products to improve patients’ quality of life. 

Our newly acquired Sancuso® franchise joined our legacy Caldolor®, Kristalose® and Vibativ® brands to help a growing number of patients during the year. 

We acquired Sancuso in early 2022 from the U.S. affiliate of Japan-based Kyowa Kirin. It’s the only FDA-approved prescription patch for the prevention of nausea and vomiting in cancer patients receiving certain chemotherapy treatments. During the year, we successfully transitioned Sancuso from Kyowa Kirin and we’re supporting the brand through our new sales division – Cumberland Oncology.

Other company highlights from 2022 include: 

• In the fourth quarter, we moved our headquarter offices to the Broadwest campus in the Vanderbilt/West End corridor of Nashville. Our move will allow us to accommodate our growth and better support our team, patients, customers and partners. 

• We entered into a new agreement with PiSA Pharmaceutical for the exclusive supply and distribution of our Caldolor® (ibuprofen) injection product in Mexico. 

• We continued to advance an innovative pipeline of new ifetroban product candidates to address unmet medical needs. We look forward to sharing the findings of these studies as they become available and to then building upon those discoveries to continue ifetroban’s development.

• We also updated our Sustainability Metrics, covering our activities pertaining to environmental, social and governance issues. Key findings include Cumberland:
  • Provided nearly 2.5 million doses of our products to patients
  • Safely disposed of over 6,000 pounds of expired or damaged products
  • Had no products recalled and no clinical trials terminated due to failure to practice good clinical standards
  • Continued to support the development and safety of our organization

As always, our success was made possible by our dedicated Cumberland team. We will continue to execute on our strategy of building a portfolio of differentiated FDA approved brands.  

We look forward to keeping you updated on our progress and developments.

2022 Company Highlights

We are pleased to report a successful 2022, as we were able to manage our business to deliver 17% revenue growth and continued positive cash flow from operations.  

Despite ongoing external challenges, we made significant progress toward our mission of providing quality products to improve patients’ quality of life. 

Our newly acquired Sancuso® franchise joined our legacy Caldolor®, Kristalose® and Vibativ® brands to help a growing number of patients during the year. 

We acquired Sancuso in early 2022 from the U.S. affiliate of Japan-based Kyowa Kirin. It’s the only FDA-approved prescription patch for the prevention of nausea and vomiting in cancer patients receiving certain chemotherapy treatments. During the year, we successfully transitioned Sancuso from Kyowa Kirin and we’re supporting the brand through our new sales division – Cumberland Oncology.

Other company highlights from 2022 include: 

• In the fourth quarter, we moved our headquarter offices to the Broadwest campus in the Vanderbilt/West End corridor of Nashville. Our move will allow us to accommodate our growth and better support our team, patients, customers and partners. 

• We entered into a new agreement with PiSA Pharmaceutical for the exclusive supply and distribution of our Caldolor® (ibuprofen) injection product in Mexico. 

• We continued to advance an innovative pipeline of new ifetroban product candidates to address unmet medical needs. We look forward to sharing the findings of these studies as they become available and to then building upon those discoveries to continue ifetroban’s development.

• We also updated our Sustainability Metrics, covering our activities pertaining to environmental, social and governance issues. Key findings include Cumberland:
  • Provided nearly 2.5 million doses of our products to patients
  • Safely disposed of over 6,000 pounds of expired or damaged products
  • Had no products recalled and no clinical trials terminated due to failure to practice good clinical standards
  • Continued to support the development and safety of our organization

As always, our success was made possible by our dedicated Cumberland team. We will continue to execute on our strategy of building a portfolio of differentiated FDA approved brands.  

We look forward to keeping you updated on our progress and developments.